Table 3.
Outcome Is Post-9/11 Change FEV1 (mL/y)
| Post-9/11 Change in FEV1 (mL/y) | Estimate | 95% CI | P Value |
|---|---|---|---|
| Intercept | −36.78 | (−45.80 to −27.76) | < .0001 |
| BHR status follow-up | |||
| Present | −15.38 | (−27.10 to −3.66) | .0104 |
| Not present | Reference | ||
| Steroid use | |||
| Ever | +13.01 | (2.10-23.93) | .0197 |
| Never | Reference | ||
| Trans 9/11 FEV1 change (post-pre per L, centered at −0.4 L) | −51.96 | (−62.42 to −41.50) | < .0001 |
| Age on 9/11 (centered at 42.6 y) | −0.01 | (−0.73 to 0.71) | .9704 |
| Height (centered at 177.9 cm) | −1.09 | (−1.87 to −0.31) | .0066 |
| Race | |||
| African American | −6.40 | (−30.29 to 17.50) | .5978 |
| White | Reference |
The intercept for this model is the estimated rate of FEV1 change (last post-first post-9/11 difference divided by time difference) for a 177.9-cm tall white participant age 42.6 y on 9/11, without BHR at follow-up, who did not report using steroids, and who had a FEV1 change of −0.4 L first post-9/11 to pre- 9/11 measurement. Negative numbers indicate decline in FEV1, positive numbers indicate increase in FEV1. See Table 1 legend for expansion of abbreviation.